Tempus AI, Inc.
TEM
Classificação em ações
#1866
Tempus AI, Inc. operates as a healthcare technology company in the United... Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
Preço da ação
$64.74
Última sincronização: 2026-10-19
Valor de mercado
$11.35B
Variação (1 dia)
0.03%
Variação (1 ano)
-29.97%
País
US
Negociar Tempus AI, Inc. (TEM)
Categoria
Healthcare
Rácio P/E de Tempus AI, Inc. (TEM)
Rácio P/E em October 2026 TTM: -47.78
De acordo com os últimos relatórios financeiros e o preço das ações da Tempus AI, Inc., o rácio P/E atual (TTM) é -47.78. No final de 2023, a empresa tinha um P/E de -30.05.
Histórico do rácio P/E da Tempus AI, Inc. de 2019 a 2026
Rácio P/E no final de cada ano
| Ano | Índice P/E | Alterar |
|---|---|---|
| 2026 (TTM) | -47.78 | 516.47% |
| 2024 | -7.75 | -74.20% |
| 2023 | -30.05 | 27.39% |
| 2022 | -23.59 | -10.57% |
| 2021 | -26.38 | -19.04% |
| 2020 | -32.58 | -42.10% |
| 2019 | -56.27 | 0.00% |
Rácio P/E para empresas semelhantes ou concorrentes
| Empresa | Rácio P/E | Diferença do rácio P/E | País |
|---|---|---|---|
| 19.68 | -141.18% |
US
|
|
| 64.40 | -234.80% |
AU
|
|
| 44.30 | -192.73% |
US
|
|
| -123.90 | 159.33% |
US
|
|
| - | - |
US
|
Como interpretar um P/E Ratio?
O rácio Preço/Lucro (P/E) mede a relação entre o preço da ação de uma empresa e o lucro por ação.
Um P/E baixo mas positivo representa uma empresa com altos lucros face à sua valorização atual e pode estar subvalorizada. Um P/E negativo elevado (perto de 0) representa perdas significativas.
Empresas com P/E acima de 30 ou negativo são geralmente vistas como "ações de crescimento", significando que os investidores esperam crescimento ou rentabilidade futura.
Empresas com P/E positivo inferior a 10 são geralmente consideradas "ações de valor", ou seja, já são muito lucrativas mas com pouco potencial de crescimento.